Please login to the form below
Chip Davies joins PhRMA
The Pharmaceutical Research and Manufacturers of America appoints AstraZeneca executive to aid transition process
AstraZeneca's (AZ) vice president of corporate external relations, Chip Davies, has joined the Pharmaceutical Research and Manufacturers of America (PhRMA) as senior operating officer to help with the association's leadership transition. He will report directly to PhRMA President and CEO Billy Tauzin, until he leaves PhRMA on June 30.
Davis will be on a leave of absence from AZ until a replacement for Tauzin is named. During this time he will work closely with David Brennan - chief executive officer and executive director of AZ and head of PhRMA's search committee - as well as the entire committee to identify Tauzin's replacement.
Share
Related Hub content
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
